# The drugmaker achieved total sales of $14.45 billion for the first quarter.

*biotech · news · 2026-05-05 · Reuters*

## Key points

- Pfizer's first quarter sales reached $14.45 billion, exceeding analysts' expectations of $13.79 billion.
- Pfizer acquired clinical-stage obesity drugmaker Metsera for $10 billion to expand its weight-loss pipeline.
- Recent settlement of Vyndamax patent disputes with generics will delay market entry of cheaper copies.
- Pfizer reaffirmed its 2026 profit and revenue guidance despite declining COVID product sales.

**Companies:** Pfizer
**Countries:** United States, India

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-beats-first-quarter-profit-estimates-strong-demand-blood-thinner-eliquis-2026-05-05/)

---

Canonical: https://newsio.io/n/493bcb17-493c-485f-a7a8-e6c0cc3acf92/the-drugmaker-achieved-total-sales-of-14-45-billion-for-the-first-quarter-pfizer
Summarized by Newsio from Reuters. https://newsio.io/how-it-works